Employees Retirement System of Texas Purchases 4,115 Shares of BioNTech SE (NASDAQ:BNTX)

Employees Retirement System of Texas grew its holdings in BioNTech SE (NASDAQ:BNTX) by 15.7% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 30,388 shares of the company’s stock after acquiring an additional 4,115 shares during the quarter. Employees Retirement System of Texas’ holdings in BioNTech were worth $2,442,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. GAMMA Investing LLC increased its position in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after purchasing an additional 150 shares during the period. Covestor Ltd grew its position in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after acquiring an additional 133 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in BioNTech by 106.3% in the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the last quarter. Crewe Advisors LLC bought a new position in BioNTech in the 1st quarter valued at approximately $75,000. Finally, American National Bank bought a new stake in BioNTech during the 1st quarter worth approximately $81,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Deutsche Bank Aktiengesellschaft upped their target price on BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, September 19th. Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $93.00 to $145.00 in a research note on Tuesday. JPMorgan Chase & Co. raised BioNTech from an “underweight” rating to a “neutral” rating and increased their price objective for the stock from $91.00 to $125.00 in a research note on Monday, September 16th. TD Cowen reduced their target price on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. Finally, HSBC raised shares of BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $127.15.

BioNTech Price Performance

BNTX stock opened at $117.64 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The firm has a market capitalization of $27.97 billion, a price-to-earnings ratio of 235.28 and a beta of 0.23. The firm has a 50 day moving average price of $93.23 and a 200-day moving average price of $91.33. BioNTech SE has a 52-week low of $76.53 and a 52-week high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. BioNTech’s revenue was down 23.3% on a year-over-year basis. During the same period last year, the business earned ($0.86) EPS. Equities research analysts forecast that BioNTech SE will post -2.87 EPS for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.